表紙
市場調査レポート

QRxPharma Limitedの製品パイプライン分析

QRxPharma Limited - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 256092
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
QRxPharma Limitedの製品パイプライン分析 QRxPharma Limited - Product Pipeline Review - 2014
出版日: 2014年06月15日 ページ情報: 英文 42 Pages
概要

QRxPharma Limitedは、疼痛管理製品などを開発、販売する医薬品企業です。

当レポートでは、QRxPharma Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

QRxPharma Limitedの基本情報

QRxPharma Limitedの概要

  • 主要情報
  • 企業情報

QRxPharma Limited:R&Dの概要

  • 主な治療範囲

QRxPharma Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ

QRxPharma Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 出願が却下された/取り下げられた製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

QRxPharma Limited:薬剤プロファイル

  • (morphine + oxycodone) IR
  • (morphine + oxycodone)
  • (morphine + oxycodone) CR
  • Q-8008
  • Q-8009
  • T-9001
  • V-0801

QRxPharma Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

QRxPharma Limited:最近のパイプライン動向

QRxPharma Limited:休止中のプロジェクト

QRxPharma Limited:企業発表

QRxPharma Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04993CDB

Global Markets Direct's, 'QRxPharma Limited - Product Pipeline Review - 2014', provides an overview of the QRxPharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of QRxPharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of QRxPharma Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of QRxPharma Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the QRxPharma Limited's pipeline products

Reasons to buy

  • Evaluate QRxPharma Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of QRxPharma Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the QRxPharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of QRxPharma Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of QRxPharma Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of QRxPharma Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • QRxPharma Limited Snapshot
    • QRxPharma Limited Overview
    • Key Information
    • Key Facts
  • QRxPharma Limited - Research and Development Overview
    • Key Therapeutic Areas
  • QRxPharma Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • QRxPharma Limited - Pipeline Products Glance
    • QRxPharma Limited - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • QRxPharma Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • QRxPharma Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • QRxPharma Limited - Drug Profiles
    • (morphine + oxycodone) IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (morphine + oxycodone)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (morphine + oxycodone) CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Q-8008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Q-8009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-9001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-0801
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • QRxPharma Limited - Pipeline Analysis
    • QRxPharma Limited - Pipeline Products by Target
    • QRxPharma Limited - Pipeline Products by Route of Administration
    • QRxPharma Limited - Pipeline Products by Molecule Type
    • QRxPharma Limited - Pipeline Products by Mechanism of Action
  • QRxPharma Limited - Recent Pipeline Updates
  • QRxPharma Limited - Dormant Projects
  • QRxPharma Limited - Company Statement
  • QRxPharma Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • QRxPharma Limited, Key Information
  • QRxPharma Limited, Key Facts
  • QRxPharma Limited - Pipeline by Indication, 2014
  • QRxPharma Limited - Pipeline by Stage of Development, 2014
  • QRxPharma Limited - Monotherapy Products in Pipeline, 2014
  • QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014
  • QRxPharma Limited - Filing rejected/Withdrawn, 2014
  • QRxPharma Limited - Phase III, 2014
  • QRxPharma Limited - Phase II, 2014
  • QRxPharma Limited - Preclinical, 2014
  • QRxPharma Limited - Pipeline by Target, 2014
  • QRxPharma Limited - Pipeline by Route of Administration, 2014
  • QRxPharma Limited - Pipeline by Molecule Type, 2014
  • QRxPharma Limited - Pipeline Products by Mechanism of Action, 2014
  • QRxPharma Limited - Recent Pipeline Updates, 2014
  • QRxPharma Limited - Dormant Developmental Projects,2014
  • QRxPharma Limited, Subsidiaries

List of Figures

  • QRxPharma Limited - Pipeline by Top 10 Indication, 2014
  • QRxPharma Limited - Pipeline by Stage of Development, 2014
  • QRxPharma Limited - Combination Treatment Modalities in Pipeline, 2014
  • QRxPharma Limited - Pipeline by Top 10 Target, 2014
  • QRxPharma Limited - Pipeline by Top 10 Route of Administration, 2014
  • QRxPharma Limited - Pipeline by Top 10 Molecule Type, 2014
  • QRxPharma Limited - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top